Table Of ContentProgress in Inflammation Research
Series Editor
Prof. Michael J. Parnham PhD
Senior Scientific Advisor
PLIVA Research Institute Ltd.
Prilaz baruna Filipovic´a 29
HR-10000 Zagreb
Croatia
Advisory Board
G. Z. Feuerstein (Wyeth Research, Collegeville, PA, USA)
M. Pairet (Boehringer Ingelheim Pharma KG, Biberach a.d. Riss, Germany)
W. van Eden (Universiteit Utrecht, Utrecht, The Netherlands)
Forthcoming titles:
Chemokine Biology – Basic Research and Clinical Application, Volume 2: Pathophysiology
of Chemokines, K. Neote, G. L. Letts, B. Moser (Editors), 2006
Toll-like Receptors in Inflammation, L. A. J. O’Neill, E. Brint (Editors), 2006
The Hereditary Basis of Rheumatic Diseases, R. Holmdahl (Editor), 2006
Endothelial Dysfunction and Inflammation, A. Graham (Editors), 2006
In vivo Models of Inflammation, 2nd edition, C. S. Stevenson, D. W. Morgan,
L. A. Marshall (Editors), 2006
(Already published titles see last page.)
Chemokine Biology – Basic Research and
Clinical Application
Volume I: Immunobiology of Chemokines
Bernhard Moser
Gordon L. Letts
Kuldeep Neote
Editors
Birkhäuser Verlag
Basel · Boston · Berlin
Editors
Bernhard Moser Gordon L. Letts Kuldeep Neote
Institute of Cell Biology NitroMed, Inc. Bone and Inflammation
University of Bern 12 Oak Park Drive Eli Lilly and Company
Baltzerstrasse 4 Bedford, MA 01730 Lilly Corporate Center
3012 Bern USA Indianapolis, IN 46285
Switzerland USA
A CIP catalogue record for this book is available from the Library of Congress, Washington D.C., USA
Bibliographic information published by Die Deutsche Bibliothek
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie;
detailed bibliographic data is available in the internet at http://dnb.ddb.de
ISBN-10: 3-7643-6825-X Birkhäuser Verlag, Basel – Boston – Berlin
ISBN-13: 978-3-7643-6825-8 Birkhäuser Verlag, Basel – Boston – Berlin
The publisher and editor can give no guarantee for the information on drug dosage and administration contained in this
publication. The respective user must check its accuracy by consulting other sources of reference in each individual case.
The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that
they are exempt from the relevant protective laws and regulations or free for general use.
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned,
specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on micro-
films or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must
be obtained.
© 2006 Birkhäuser Verlag, P.O. Box 133, CH-4010 Basel, Switzerland
Part of Springer Science+Business Media
Printed on acid-free paper produced from chlorine-free pulp. TCF ∞
Cover design: Markus Etterich, Basel
Cover illustration: see page 159. With friendly permission of Osamu Yoshie.
Printed in Germany
ISBN-10: 3-7643-6825-X e-ISBN: 3-7643-7423-3
ISBN-13: 978-3-7643-6825-8
9 8 7 6 5 4 3 2 1 www.birkhauser.ch
Contents
List of contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Introduction
Marco Baggiolini
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Cellular targets in innate and adaptive immunity
Charles Mackay and Bernhard Moser
Traffic of T lymphocytes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
William W. Agace and Bernhard Homey
Lymphocyte homing to peripheral epithelial tissues. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Chenggang Jin and Craig T. Morita
Chemokine biology of NK cells and γδ T cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Federica Sallusto, Alfonso Martín-Fontecha and Antonio Lanzavecchia
Dendritic cell traffic control by chemokines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Mario Mellado, Carlos Martínez-A., José Miguel Rodríguez-Frade
Chemokine receptor-mediated signal transduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Lixin Liu and Paul Kubes
Chemokines in leukocyte transendothelial migration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Mariagrazia Uguccioni and Basil O. Gerber
Natural chemokine antagonism and synergism. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Effector cell traffic-unrelated functions
Ning Zhang and Joost J. Oppenheim
Crosstalk between chemokine, opioid and vanilloid receptors. . . . . . . . . . . . . . . . . . . . 137
Osamu Yoshie
Antimicrobial and related activities of chemokines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
Alexandra Lucas, Dana McIvor and Grant MacFadden
Virus-encoded chemokine modulators as novel anti-inflammatory reagents . . . . 165
Paola Romagnani, Laura Lasagni and Sergio Romagnani
Chemokine receptors in tissue cells and angiogenesis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
List of contributors
William W. Agace, Immunology Section, Lund University, BMC I-13, 22184 Lund,
Sweden; e-mail: [email protected]
Marco Baggiolini, Università della Svizzera Italiana, Via Lambertenghi 10A, 6904
Lugano, Switzerland; e-mail: [email protected]
Basil O. Gerber, Division of Allergology, Dept. of Rheumatology & Clin. Immunol-
ogy/Allergology, Sahlihaus 1, Inselspital, 3010 Berne, Switzerland
Bernhard Homey, Department of Dermatology, Heinrich-Heine-University,
Moorenstr. 5, 40225 Düsseldorf, Germany;
e-mail: [email protected]
Chenggang Jin, Division of Rheumatology, Department of Internal Medicine and
the Interdisciplinary Group in Immunology, University of Iowa College of Medicine,
EMRB 340F, Iowa City, IA 52242, USA
Paul Kubes, Immunology Research Group, Department of Physiology and Bio-
physics, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, T2N
4N1, Canada; e-mail: [email protected]
Antonio Lanzavecchia, Institute for Research in Biomedicine, Via Vincenzo Vela 6,
6500 Bellinzona, Switzerland; e-mail: [email protected]
Laura Lasagni, Center of Excellence for Research, Transfer and High Education
DENOthe of the University of Florence, 50134 Italy; e-mail: [email protected]
Lixin Liu, Immunology Research Group, Department of Physiology and Biophysics,
University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 4N1,
Canada
vii
List of contributors
Alexandra Lucas, BioTherapeutics Research Group/Vascular Biology Reasearch
Group, Robarts Research Institute, and Dept. Microbiology and Immunology, Uni-
versity of Western Ontario, London, Ontario, Canada N6G 2K5;
e-mail: [email protected]
Charles R. Mackay, Garvan Institute of Medical Reasearch, Darlinghurst NSW
2010, Australia
Alfonso Martín-Fontecha, Institute for Research in Biomedicine, Via Vincenzo Vela
6, 6500 Bellinzona, Switzerland; e-mail: [email protected]
Carlos Martínez-A., Department of Immunology and Oncology, Centro Nacional
de Biotecnología/CSIC, Darwin, 3, Campus de Cantoblanco, 28049 Madrid, Spain
Grant McFadden, BioTherapeutics Research Group, Robarts Research Institute,
and Dept. Microbiology and Immunology, University of Western Ontario, London,
Ontario, Canada N6G 2K5; e-mail: [email protected]
Dana McIvor, BioTherapeutics Research Group/Vascular Biology Reasearch Group,
Robarts Research Institute, and Dept. Microbiology and Immunology, University of
Western Ontario, London, Ontario, Canada N6G 2K5
Mario Mellado, Department of Immunology and Oncology, Centro Nacional de
Biotecnología/CSIC, Darwin, 3, Campus de Cantoblanco, 28049 Madrid, Spain;
e-mail: [email protected]
Craig T. Morita, Division of Rheumatology, Department of Internal Medicine and
the Interdisciplinary Group in Immunology, University of Iowa College of Medicine,
EMRB 340F, Iowa City, IA 52242, USA; e-mail: [email protected]
Bernhard Moser, Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012
Bern, Switzerland; e-mail: [email protected]
Joost J. Oppenheim, Laboratory of Molecular Immunoregulation, Intramural
Research Support Program, Building 560, Room 21-89A, Frederick, MD 21702-
1201, USA; e-mail: [email protected]
José Miguel Rodríguez-Frade, Department of Immunology and Oncology, Centro
Nacional de Biotecnología/CSIC, Darwin, 3, Campus de Cantoblanco, 28049
Madrid, Spain; e-mail: [email protected]
viii
List of contributors
Paola Romagnani, Center of Excellence for Research, Transfer and High Education
DENOthe of the University of Florence, 50134 Italy;
e-mail: [email protected]
Serigio Romagnani, Center of Excellence for Research, Transfer and High Educa-
tion DENOthe of the University of Florence, 50134 Italy;
e-mail: [email protected]
Federica Sallusto, Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500
Bellinzona, Switzerland; e-mail: [email protected]
Mariagrazia Uguccioni, Institute for Research in Biomedicine, 6500 Bellinzona,
Switzerland
Osamu Yoshie, Department of Microbiology, Kinki University School of Medicine,
Osaka-Sayama, Osaka 589-8511, Japan; e-mail: [email protected].
Ning Zhang, Laboratory of Molecular Immunoregulation, Intramural Research
Support Program, Building 560, Room 21-89A, Frederick, MD 21702-1201, USA
ix
Preface
The discovery of interleukin-8 close to 20 years ago initiated a new field of research
touching on many aspects of immunology and inflammation. Interleukin-8 is just
one member of a large class of structurally-related chemoattractant proteins, known
as chemokines. Chemokines are involved in the traffic control of leukocytes, which
bear the corresponding chemokine receptors on their surfaces. They are the largest
family of cytokines in the human genome. The discovery of chemokines and
chemokine receptors has been largely fueled by the human genome sequencing
efforts. To date, there are more then 45 known chemokines and approximately 17
receptors.
Chemokine research over the last two decades has focused on their role in leuko-
cyte migration. It is now clear that chemokines affect all aspects of immunology and
contribute to the pathology of a large number of inflammatory and immune-medi-
ated diseases, such as rheumatoid arthritis, pulmonary inflammatory diseases and
multiple sclerosis. Their fundamental contributions to chronic inflammatory dis-
eases make them a principal target for the development of novel, anti-inflammato-
ry therapeutics. More recently, it has become apparent that chemokines have an
essential role in diverse processes distinct from their function in immunity, includ-
ing tumor cell growth and metastasis, atherosclerosis and angiogenesis. This book
gives a state-of-the-art account of recent developments in this field in the form of
summaries written by highly regarded experts.
Volume I is focused on basic principles and progress in chemokine biology. The
emphasis is on the role of chemokines in leukocytes function and on their role in
dendritic cell biology. In addition, chemokine receptor signaling and natural antag-
onism of the receptors is covered. Finally aspects of chemokine biology, as pertains
to endothelial cells and angiogenesis, are discussed.
Volume II deals with issues related to the pathophysiology of chemokines,
chemokine-related drug development and potential therapeutic applications. It is
also published in the book series Progress in Inflammation Researchand is entitled
Chemokine Biology – Basic Research and Clinical Application. Volume II: Patho-
physiology of Chemokines (2006, Birkhäuser, ISBN 3-7643-7195-1). These books
provide both introductory and novel information for a broad readership, including
clinicians and biomedical scientists.
September 2005 Bernhard Moser
Gordon L. Letts
Kuldeep Neote
xi
